KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查 入排置信度 0.85

Perioperative optimization with nutritional supplements in patients undergoing gastrointestinal surgery for cancer: A randomized, placebo-controlled feasibility clinical trial.

Pablo E Serrano, Sameer Parpia, Marko Simunovic, Emmanuelle Duceppe, Maria Ines Pinto-Sanchez, Mohit Bhandari, Mark Levine

Surgery 172(2) 670-676

PMID35606184
PMCID-
DOI10.1016/j.surg.2022.04.001
发表日期2022-05-23
入排依据:The study is a randomized, placebo-controlled pilot/feasibility trial in human oncology patients. However, it fails inclusion due to: 1) The intervention is nutritional supplements (non-drug), not a drug-containing intervention. 2) It is a Phase II/feasibility study, not a definitive Phase III trial. 3) The primary endpoint is enrollment feasibility, and secondary endpoints include compliance and postoperative complications (not time-to-event efficacy like OS, PFS, DFS). No Kaplan-Meier or HR is reported for an efficacy endpoint.
摘要

摘要

BACKGROUND: Perioperative nutritional supplementation may improve outcomes. Trials have not investigated the role of combination strategy using different types of nutritional supplements. METHODS: We conducted a single-site randomized pilot trial, among gastrointestinal cancer patients undergoing surgery, comparing perioperative nutritional supplements versus placebo (1 placebo to each supplement), to determine feasibility of a larger trial. Intervention, administered in sequence, included: protein supplementation (preoperative day 30-6), protein supplementation rich in arginine and omega-6 (preoperative day 5-1, and postoperative day 1-5), and carbohydrate loading (surgery day). Primary outcome was enrollment. Secondary outcomes included participant compliance with study supplements (target ≥70% of total packets). We planned protocol modifications to improve enrollment and compliance. Postoperative complications were described. RESULTS: Over 18 months, 495 patients were screened, 144 were deemed eligible, and 71 consented to participate, resulting in an enrollment fraction of 71/144 (49%, 95% confidence interval: 41%-57%). 'Too much burden' was the most common reason for refusal to participate (34%). Participants' median overall compliance with study packets was 80%. Protocol modifications (decreasing the interval from enrollment to surgery from 4 to 2 weeks and decreasing length of baseline assessment) did not impact enrollment or compliance. Postoperative complications were similar between control (18/31 [58%, 95% confidence interval: 4-74]), and intervention (22/34 [65%, 95% confidence interval: 48-79]) arms, with a higher proportion of infectious complications in the control arm (16/31, 52% vs 12/34, 35%). CONCLUSION: Results from this pilot suggest a larger phase III trial is feasible. Postoperative infectious complications were common, making this a suitable outcome of interest.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。